Best Tesamorelin stacks for fat reduction, recovery, and HGH optimization

The best tesamorelin stacks are usually built around peptides or therapies that support growth hormone (GH) activity, recovery, body composition, and metabolic health without over-stimulating the GH-IGF-1 axis. Tesamorelin itself is already a potent growth hormone-releasing hormone (GHRH) analog with well-documented effects in visceral fat reduction and improvement of metabolic markers [1–6]. However, most additional combinations primarily rely on theoretical synergy, smaller studies, or practices used in wellness and biohacking settings, rather than large-scale clinical trials evaluating specific peptide „stacks.” For this reason, such combinations should be used cautiously and preferably under the supervision of a specialist.

Tesamorelin works by stimulating GHRH receptors in the pituitary gland, increasing natural pulsatile GH secretion and raising insulin-like growth factor-1 (IGF-1) levels [1,2]. Clinical studies show that this can lead to reduced visceral fat, improved hepatic steatosis, support for lean body mass, and enhanced lipid metabolism [3–6]. Since tesamorelin already strongly activates the GHRH pathway, most common stacks aim to supplement its action rather than replicate it.

One of the most discussed combinations is tesamorelin with ipamorelin. Ipamorelin is a growth hormone secretagogue (GHS) peptide and a ghrelin receptor agonist that stimulates GH release through a different mechanism than tesamorelin [7–10]. Tesamorelin acts via GHRH receptors, while ipamorelin activates ghrelin receptors (GHS-R1a). As both peptides affect different parts of the growth hormone regulatory system, some individuals believe their combination may support stronger or more natural GH pulsatility.

Ipamorelin is often recognized as one of the more selective GH secretagogues due to its lesser induction of cortisol and prolactin release compared to older GHRPs [7,8]. Although large clinical studies directly analyzing a tesamorelin and ipamorelin stack are currently lacking, the scientific rationale for such a combination is considered biologically plausible.

From a body composition perspective, tesamorelin has significantly stronger clinical evidence regarding visceral fat reduction and improved metabolic health. Clinical studies have repeatedly demonstrated a reduction in visceral fat of approximately 15–18% during tesamorelin therapy [3–5]. Research on ipamorelin, on the other hand, focuses primarily on GH secretion, recovery, sleep quality, and anabolic signaling, rather than directly on fat-reducing effects [7–10]. For this reason, tesamorelin is typically viewed as the primary component of a stack responsible for fat reduction and improving metabolic parameters.

Another commonly discussed combination is tesamorelin with testosterone replacement therapy (TRT). Both therapies work through different hormonal systems and can provide complementary effects on body composition. Tesamorelin primarily focuses on reducing visceral fat and activating the GH-IGF-1 axis, while TRT supports muscle protein synthesis, strength, libido, energy levels, and bone density. Clinical studies have shown that tesamorelin improves visceral fat, liver steatosis, triglycerides, and metabolic markers without significantly worsening glycemic control [3-6]. However, large randomized trials analyzing the concurrent use of tesamorelin and TRT are still lacking.

Some individuals also combine tesamorelin with recovery-supporting peptides like BPC-157 or TB-500, particularly in sports and wellness settings. However, it's important to emphasize that high-quality clinical research on such combinations is virtually non-existent. Most available information stems from animal studies, experimental peptide literature, or anecdotal reports, rather than controlled clinical trials. From a scientific standpoint, the strongest evidence for tesamorelin still pertains to visceral fat reduction, improvement of fatty liver, and metabolic health, rather than extreme muscle mass development.

It is also worth understanding that combining multiple GH-stimulating peptides may increase the risk of adverse events related to elevated GH and IGF-1 activity. Adverse events reported in studies on tesamorelin included:

• Water retention and swelling
• Stiffness or joint pain
• Injection site reactions
• numbness or tingling
• skin redness
• elevated IGF-1 levels [3–6]

Similar side effects may also occur when using ipamorelin and other GH secretagogues [7–10]. Excessive stimulation of the GH–IGF-1 axis may increase the risk of insulin resistance, fluid retention, or hormonal disorders in some individuals. For this reason, combining several GH peptides at full doses does not always provide additional benefits proportional to the potential risks.

From an evidence-based medicine perspective, tesamorelin alone currently has significantly stronger clinical support than most peptide stacks promoted in the context of anti-aging, HGH optimization, or bodybuilding. Human studies have consistently demonstrated reductions in visceral fat, improvement in fatty liver, beneficial effects on lipid profiles, support for mitochondrial function, and preservation of muscle tissue [3-6]. Additional combinations may theoretically offer complementary benefits, however, their clinical validation remains limited.

Generally speaking, the best stack with tesamorelin depends on the goal. For visceral fat reduction and improved metabolic health, tesamorelin alone already has strong clinical evidence. In broader protocols aimed at GH optimization and recovery, combinations like tesamorelin with ipamorelin are sometimes considered, as both peptides stimulate different pathways that regulate GH secretion. However, most such stacks remain experimental, and the long-term safety of combining multiple GH secretagogues has not yet been fully established in human clinical trials.

Disclaimer

This content is for educational and informational purposes only and does not constitute medical, diagnostic, or therapeutic advice. Tesamorelin is a prescription drug approved for specific medical indications, whereas many of the peptide combinations discussed online remain experimental or are used off-label. Peptides that affect growth hormone and IGF-1 pathways may carry risks, including edema, insulin resistance, hormonal imbalances, and elevated IGF-1 levels. Any hormone or peptide therapy should be conducted exclusively under the supervision of a qualified specialist with appropriate laboratory monitoring. Research-use-only peptides offered by suppliers such as Semax Polska are intended solely for laboratory and scientific research.

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548730/
2. PubChem. (2025). Tesamorelin Compound Summary. National Center for Biotechnology Information, National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
3. Falutz, J., Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
4. Falutz, J., Allas, S., Mamputu, J. C., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
5. Stanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
6. Stanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Agyapong, G., Torriani, M., Chung, R. T., & Grinspoon, S. K. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
7. Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. https://doi.org/10.1023/A:1018955126402
8. Johansen, P. B., Hansen, K. T., Andersen, J. V., & Johansen, N. L. (1998). Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica, 28(11), 1083–1092. https://doi.org/10.1080/004982598238976
9. Johansen, P. B., Nowak, J., Skjaerbaek, C., Pedersen, S. B., Flyvbjerg, A., & Andreassen, T. T. (1999). Ipamorelin, a new growth hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106–113. https://doi.org/10.1054/ghir.1999.9998
10. Jiménez-Reina, L., Cañete, R., de la Torre, M. J., & Bernal, G. (2002). Effect of chronic treatment with the growth hormone secretagogue ipamorelin in young female rats: In vitro somatotropic response. Histology and Histopathology, 17(3), 707–714. https://doi.org/10.14670/HH-17.707